{
    "paper_id": "6f07f19d3582eee1a3564ca23aa83d68d99bda9b",
    "metadata": {
        "title": "Supplementary Appendix",
        "authors": []
    },
    "abstract": [],
    "body_text": [
        {
            "text": "Throat swab sampling for study-related monitoring was performed following guidance from manufacturer (Copan Diagnostics Inc., Murrieta, CA, USA). Samples were stored and sent for batch testing after all follow-ups were finished. The quantitative RT-PCR testing methods in this study were validated in Teddy Clinical Research Laboratory (Wuhan City, China) as shown below.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Quantitative Viral RNA Testing"
        },
        {
            "text": "We did method validation including precision, accuracy, specificity and sensitivity following the guidelines of CAP, CLSI and MIQE. Due to the limited number and types of samples, 10 nasopharyngeal swab samples previously tested as SARS-CoV-2 positive using commercial in vitro diagnostic kit were used for the validation tests. The summary results are as follows:",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Quantitative Viral RNA Testing"
        },
        {
            "text": "Precision Validation: The coefficient of variation (CV) value of all validation samples was less than 15%, which met the validation criteria and passed the inter and intra batch precision validation.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Quantitative Viral RNA Testing"
        },
        {
            "text": "The CV value of all validation samples was less than 15% and the bias was less than 50%, which met the validation criteria and passed the accuracy verification.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Accuracy Validation:"
        },
        {
            "text": "The specificity is defined as the consistency between the test results in theory and the actual test results. We used 10 known clinical samples for validation. The CV value of all validation samples was less than 15%. The test results were 100% consistent with the actual test results Sensitivity Validation: E gene RNA standard provided by Roche Diagnostics was used for sensitivity validation test. LLOQ (lowest limit of quantification) and LOD (Limit of detection) were determined using E gene RNA standard.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Specificity Validation:"
        },
        {
            "text": "The lower limit of quantifcation for this assay is 10 copies/ul and the limit of detection of PCR assay is 1 copy/ul. The kit contains specific primer and probes designed to detect three genes: RNA dependent RNA polymerase (RdRP), N gene and E gene. E-gene was used for virus screening to eliminate NC_014470Bat SARS-related CoVC; and RdRP and N genes are used for confirmation of SARS-CoV-2 infection.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Specificity Validation:"
        },
        {
            "text": "Although RdRp gene was specific for SARS-CoV-2, we selected E gene to quantify the viral load instead of RdRp gene because the amplification efficiency for RdRp gene was lower than E gene. The quantification was performed by using E-gene RNA standards provided by Roche Diagnostics (Shanghai) Ltd.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Specificity Validation:"
        },
        {
            "text": "E-gene assay in the kit detects both SARS and SARS-CoV-2 as well as other bat-associated SARSrelated viruses (Sarbecovirus). There is no cross reactivity found with common human respiratory CoVs (NL63, 229E, HKU, OC43) or MERS-CoV by gene sequence analysis. Since all samples in this study were from patients clinically diagnosed with COVID-19 pneumonia in Wuhan (and no SARS CoV infection has been detected), it is logical that we used the E gene target for the quantification of the viral load of the samples. Detection of RdRp and N genes were also tested for all patient's first visit samples.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Specificity Validation:"
        },
        {
            "text": "Assay controls included the addition of EAV RNA Extraction control (LightMix\u00ae, TIB Germany) directly to samples as control to monitor the entire process which is from RNA extraction to gene detection, addition of both negative (water) and positive controls (LightMix\u00ae) on different positions of each 96-well PCR plate to monitor the amplification process, standard laboratory processes to mitigate cross contamination",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Specificity Validation:"
        },
        {
            "text": "The viral RNA was extracted using MagNA Pure 96 DNA and Viral NA Small Volume kit in MagNA pure 96 system (Roche Diagnostics). 200 ul of each types of samples was added to each wells of 96 deep well plate previously filled with 250 ul of External Lysis buffer (provided in the kit) followed by 60\u2103 1h incubation to inactivate the virus before RNA extraction. 10 ul of EAV control was also added to each well. RNA extraction was performed in MagNA Pure 96 System which is a closed system and fully automated. 10 ul of Purified virus RNA was then added to pre-prepared PCR plate with each well contains 10 ul PCR reaction buffer in biological safety cabinet. qPCR reactions were performed according to instruction. Reagent preparation, sample purification and PCR were performed in separate rooms with passing windows to avoid cross contaminations. All rooms are negative pressured and have buffer rooms for changing. Positive control and standards for quantification were prepared in another room and add into PCR plate only in sample extraction room to avoid contamination. *This total excludes 3 patients who died within 24 hours of randomization and did not receive lopinavir/ritonavir. \u00a7Differences were expressed as rate differences or median difference (Hodges-Lehmann estimate) and 95% confidence intervals. \u2020 The hazard ratio was estimated by Cox proportional risk model. Clinical deterioration rate Figure S5 . Proportional distribution of primary endpoint categories at day1, 7, 14 and 28 in the intention-to-treat population Proportion of severe outcomes according to 7-category ordinal scale that ranges from 1 (discharged with normal activity) to 7 (death). 2 Not hospitalized, but unable to resume normal activities; 3",
            "cite_spans": [],
            "ref_spans": [
                {
                    "start": 1407,
                    "end": 1416,
                    "text": "Figure S5",
                    "ref_id": null
                }
            ],
            "section": "Specificity Validation:"
        },
        {
            "text": "Hospitalized, not requiring supplemental oxygen; 4 Hospitalized, requiring supplemental oxygen; 5",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Specificity Validation:"
        },
        {
            "text": "Hospitalized, requiring high-flow nasal oxygen (HFNC)and/or non-invasive mechanical ventilation (IMV); 6 Hospitalized, requiring ECMO and/or IMV; 7 Death. ",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Specificity Validation:"
        }
    ],
    "bib_entries": {
        "BIBREF0": {
            "ref_id": "b0",
            "title": "AUC in mITT analysis set (excluding patients without any detectable viral RNA), as determined by quantitative reverse transcription-polymerase chain reaction (qRT-PCR) analysis. Results less than the lower limit of quantification of PCR assay and greater than the limit of qualitative detection are imputed with",
            "authors": [],
            "year": null,
            "venue": "",
            "volume": "1",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF1": {
            "ref_id": "b1",
            "title": "copies/mL; results of patients with viral negative RNA are imputed with 0 log10 copies/mL. AUC, area under the curve. \u00a7Differences were expressed as rate differences or Hodges-Lehmann estimator differences and 95% confidence intervals",
            "authors": [],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        }
    },
    "ref_entries": {
        "FIGREF0": {
            "text": "of Contents Supplementary Methods ......................................................................................................... 2 Quantitative Viral RNA Testing ...................................................................................................... 2 Table S1. Outcomes in the modified intention-to-treat population. .......................................... 5 Table S2. Virological outcomes in the modified intention-to-treat population. ....................... Kaplan Meier plot of time-to-clinical improvement in the modified intention-totreat population. ......................................................................................................................... Kaplan Meier plot of time-to-clinical improvement by duration of illness (\u2264 12 days [Panel A] vs > 12 days [Panel B]) in the intention-to-treat population. ............................ Kaplan Meier of time-to-clinical improvement by severity of illness (NEWS2 score > 5 [Panel A] vs \u2264 5[Panel B]) in the intention-to-treat population. ............................. Kaplan Meier of time-to-clinical deterioration in the intention-to-treat population. .................................................................................................................................................. Proportional distribution of primary endpoint categories at day1, 7, 14 and 28 in the intention-to-treat population .............................................................................................. SARS-CoV-2 viral RNA load over time from baseline by qPCR on throat swabs (viral positive population) by duration of illness (\u2264 12 days [Panel A] vs > 12 days [Panel B]) in the modified intention-to-treat population. .......................................................................... Summary of Protocol Violations. ....................................................................... 134 Supplementary Methods",
            "latex": null,
            "type": "figure"
        },
        "FIGREF1": {
            "text": "Number (percentage) or median (interquartile range) is summarized as appropriate. Abbreviation: ICU = intensive care unit; HFNC = high-flow nasal oxygen therapy; IMV = invasive mechanical ventilation; ECMO = extracorporeal membrane oxygenation; TTCI = time to clinical improvement. Clinical improvement (the event) was defined as a decline of two categories on the modified seven-category ordinal scale of clinical status, or hospital discharge.",
            "latex": null,
            "type": "figure"
        },
        "FIGREF2": {
            "text": "SARS-CoV-2 viral RNA load over time from baseline by qPCR on throat swabs (viral positive population) by duration of illness (\u2264 12 days [Panel A] vs > 12 days [Panel B]) in the modified intention-to-treat population.",
            "latex": null,
            "type": "figure"
        },
        "FIGREF3": {
            "text": "Summary the percentage is the total number of patients in each group. * The attending physician refused to prescribe lopinavir-ritonavir after randomization",
            "latex": null,
            "type": "figure"
        },
        "TABREF0": {
            "text": "",
            "latex": null,
            "type": "table"
        },
        "TABREF1": {
            "text": "Outcomes in the modified intention-to-treat population.",
            "latex": null,
            "type": "table"
        },
        "TABREF2": {
            "text": "Virological outcomes in the modified intention-to-treat population.Figure S2. Kaplan Meier plot of time-to-clinical improvement by duration of illness (\u2264 12 days [Panel A] vs > 12 days [Panel B]) in the intention-to-treat population.Figure S3. Kaplan Meier of time-to-clinical improvement by severity of illness (NEWS2 score > 5 [Panel A] vs \u2264 5[Panel B]) in the intention-to-treat population.Figure S4. Kaplan Meier of time-to-clinical deterioration in the intention-to-treat population.",
            "latex": null,
            "type": "table"
        }
    },
    "back_matter": []
}